Letter Waiver to Credit Agreement among Alpharma Inc., Bank of America, and Other Lenders (August 14, 2003)

Summary

Alpharma Inc. and its lenders, including Bank of America and several financial institutions, agree to a waiver of certain requirements in their existing Credit Agreement to allow Alpharma to sell its generic pharmaceutical business in France. The waiver requires Alpharma to use all proceeds from the sale to repay outstanding loans within five business days. The agreement also reduces the Swing Line Facility from $50 million to $35 million and releases related collateral. All other terms of the original Credit Agreement remain in effect.

EX-10.1 3 waiver.htm LETTER WAIVER TO THE CREDIT AGREEMENT Form

LETTER WAIVER

Dated as of August 14, 2003

To the banks, financial institutions
and other institutional lenders
(collectively, the "Lenders")
parties to the Credit Agreement
referred to below and to Bank of America,
as administrative agent (the "Administrative Agent") for the Lenders

Ladies and Gentlemen:

We refer to the Credit Agreement dated as of October 5, 2001, as amended by Amendment No. 1 thereto dated as of December 16, 2002 and Amendment No. 2 thereto dated as of April 3, 2003 (such Credit Agreement, as so amended, the "Credit Agreement") among the undersigned and you. Capitalized terms not otherwise defined in this Letter Waiver have the same meanings as specified in the Credit Agreement.

We hereby request that you waive, solely with respect to the French Sale (as defined below), the requirements of Section 5.02(e)(v)(D) of the Credit Agreement. As used in this Letter Waiver, the term "French Sale" means the sale, transfer or other disposition, in one transaction or series of related transactions, by the Company of those assets and properties constituting its generic pharmaceutical business conducted in France (the "Subject Property"). It is understood and agreed that all Net Cash Proceeds received by or on behalf of the Company in respect of the French Sale will be applied by the Company pursuant to Section 2.06(b) of the Credit Agreement within five Business Days of receipt to prepay an aggregate principal amount of the Advances equal to 100% of Net Cash Proceeds so received. In order to effect the French Sale, we also hereby request that you release the Subject Property from any liens and security interests created and evidenced by the Collateral Documents . In connection with this request, we hereby certify that no Default has occurred and that, except with respect to Section 5.02(e)(v)(D) of the Credit Agreement, which is the subject of this Letter Waiver, the sale of the Subject Property is in compliance with the Loan Documents.

We also hereby request that any and all interest rate Hedge Agreements permitted under Article V of the Credit Agreement that are entered into on and after the date hereof by and between any Loan Party and any Hedge Bank constitute "Secured Hedge Agreements" for all purposes of the Credit Agreement and the other Loan Documents.

We hereby agree that, upon the effectiveness of this Letter Waiver, the Swing Line Facility shall be reduced from $50,000,000 to $35,000,000.

This Letter Waiver shall become effective as of the date first above written when, and only when, the Administrative Agent shall have received counterparts of this Letter Waiver executed by us and the Required Lenders and the Swing Line Bank or, as to any of the Lenders, advice satisfactory to the Administrative Agent that such Lender has executed this Letter Waiver, and the consent attached hereto executed by each Grantor. This Letter Waiver is subject to the provisions of Section 8.01 of the Credit Agreement.

The Credit Agreement, the Notes and each of the other Loan Documents, except to the extent of the waiver specifically provided above, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed. Without limiting the generality of the foregoing, the Collateral Documents and all of the Collateral described therein do and shall continue to secure the payment of all Obligations of the Loan Parties under the Loan Documents. The execution, delivery and effectiveness of this Letter Waiver shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under any of the Loan Documents, nor constitute a waiver of any provision of any of the Loan Documents.

If you agree to the terms and provisions of this Letter Waiver, please evidence such agreement by executing and returning (i) one counterpart of this waiver by fax to Cissie Abraham, Shearman & Sterling LLP (telephone ###-###-####, fax ###-###-####) no later than noon on August 14, 2003 and (ii) two original counterparts of this waiver to Cissie Abraham, Shearman & Sterling LLP, 599 Lexington Avenue, New York, New York 10022, at your earliest convenience.

This Letter Waiver may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Waiver by telecopier shall be effective as delivery of a manually executed counterpart of this Letter Waiver.

This Letter Waiver shall be governed by, and construed in accordance with, the laws of the State of New York.

[remainder of this page intentionally left blank]

Very truly yours,

ALPHARMA INC.

By: /s/ Albert N. Marchio, II
Title: Vice President and Treasurer

Agreed as of the date first above written:

BANK OF AMERICA, N.A.,
as Administrative Agent, as Swing Line Bank and as Lender

By: /s/ Joseph L. Corah
Title: Principal

Agreed as of the date first above written:

BANK OF AMERICA, N.A.
By: /s/ Joseph L. Corah
Title: Principal

BNP PARIBAS
By: /s/ Richard Pace
Title: Director

By: /s/ Shayn P. March
Title: Vice President

BNP PARIBAS, OSLO BRANCH
By: /s/ Jean-Claude Helle
Title: General Manager

CANADIAN IMPERIAL BANK OF COMMERCE
By: /s/ John F. Burke
Title: Authorized Signatory

CITICORP USA, INC.
By: /s/ Allen Fisher
Title: Vice President

DEN NORSKE BANK ASA
By: /s/ Terje Turnes
Title: General Manager

FLEET NATIONAL BANK
By: /s/ Virginia C. Stelzenthaler
Title: Managing Director

HSH NORDBANK COPENHAGEN BRANCH
By: /s/ Steffen E. Andersen
Title:

By: /s/ Finn Bergmann
Title:

IKB CAPITAL CORPORATION
By: /s/ David Snyder
Title: President

NATIONAL CITY
By: /s/ Michael A. Moose
Title: Account Officer

UNION BANK OF NORWAY
By: /s/ Sven Hove
Title: General Manager

 

AERIES FINANCE-II LTD.
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

AIM FLOATING RATE FUND
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

AMARA 2 FINANCE, LTD.
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

APEX (Trimaran) CDO I, LTD.
By:/s/ David M. Millison
Title: Managing Director

AVALON CAPITAL LTD.
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

AVALON CAPITAL LTD. 2
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

BLACK DIAMOND CLO 1996-1 LTD.
By:/s/ Alan Corkish
Title: Director

BLACK DIAMOND CLO 2000-1 LTD.
By:/s/ Alan Corkish
Title: Director

BLACK DIAMOND INTERNATIONAL FUNDING, LTD
By: /s/ Alan Corkish
Title: Director

CHARTER VIEW PORTFOLIO
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

DENALI CAPITAL CLO I, LTD
By: /s/ John P. Thacker
Title: Chief Credit Officer

DENALI CAPITAL CLO II, LTD
By: /s/ John P. Thacker
Title: Chief Credit Officer

DENALI CAPITAL CLO III, LTD
By: /s/ John P. Thacker
Title: Chief Credit Officer

DIVERSIFIED CREDIT PORTFOLIO LTD.
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

FLAGSHIP CLO 2001-1
By: /s/ Colleen Cunliffe
Title: Director

FLAGSHIP CLO II
By: /s/ Colleen Cunliffe
Title: Director

INVESCO CBO 2000-1 LTD.
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

SAGAMORE CLO LTD.
By: /s/ Thomas H.B. Ewald
Title: Authorized Signatory

SEQUILS-LIBERTY, LTD.
By:/s/ Thomas H.B. Ewald
Title: Authorized Signatory

TRS I LLC
By:/s/ Alice L. Wagner
Title: Vice President

VAN KAMPEN CLO I, LIMITED
By: /s/ Christina Jamieson
Title: Vice President

VAN KAMPEN CLO II, LIMITED
By: /s/ Christina Jamieson
Title: Vice President

VAN KAMPEN SENIOR INCOME TRUST
By: /s/ Christina Jamieson
Title: Vice President

VAN KAMPEN SENIOR LOAN FUND
By: /s/ Christina Jamieson
Title: Vice President

 

CONSENT

Dated as of August 14, 2003

Each of the undersigned, as grantors under the Collateral Documents to which each is a party and as Guarantors under, as applicable, the (i) Parent Guaranty dated as of October 5, 2001, (ii) Subsidiary Guaranty dated as of October 5, 2001 or (iii) Subsidiary Guaranty dated as of December 26, 2001, in each case in favor of the Secured Parties referred to therein (collectively, the "Guaranty"), hereby consents to the foregoing Letter Waiver and hereby confirms and agrees that (a) notwithstanding the effectiveness of such Letter Waiver, the Guaranty is, and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects except that, on and after the effectiveness of such Letter Waiver, each reference in the Guaranty to the "Credit Agreement", "thereunder", "thereof" or words of like import shall mean and be a reference to the Credit Agreement, as modified by such Letter Waiver, and (b) each of the Collateral D ocuments to which such Grantor is a party and all of the Collateral described therein do, and shall continue to, secure the payment of all of the Secured Obligations (in each case, as defined therein).

ALPHARMA OPERATING CORPORATION

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA USPD INC.

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA U.S. INC.

By: /s/ Robert F. Wrobel
Title: Secretary

BARRE PARENT CORPORATION

By: /s/ Robert F. Wrobel
Title: Secretary

G.F. REILLY COMPANY

By: /s/ Robert F. Wrobel
Title: Secretary

PARMED PHARMACEUTICALS, INC.

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA EURO HOLDINGS INC.

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA (BERMUDA) INC.

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA USHP INC.

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA US PHARMACEUTICAL LLC

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA ANIMAL HEALTH COMPANY

By: /s/ Robert F. Wrobel
Title: Secretary

MIKJAN CORPORATION

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA NW INC.

By: /s/ Robert F. Wrobel
Title: Secretary

NMC LABORATORIES, INC.

By: /s/ Robert F. Wrobel
Title: Secretary

US ORAL PHARMACEUTICALS PTY LTD

By: /s/ Robert F. Wrobel
Title: Secretary

FAULDING HOLDINGS INC.

By: /s/ John W. LaRocca
Title: Assistant Secretary

FAULDING PHARMACEUTICALS INC.

By: /s/ John W. LaRocca
Title: Assistant Secretary

POINT HOLDINGS INC.

By: /s/ John W. LaRocca
Title: Assistant Secretary

PUREPAC PHARMACEUTICAL HOLDINGS INC.

By: /s/ Robert F. Wrobel
Title: Secretary

FAULDING LABORATORIES INC.

By: /s/ Robert F. Wrobel
Title: Secretary

PUREPAC PHARMACEUTICAL CO.

By: /s/ Robert F. Wrobel
Title: Secretary

ALPHARMA INVESTMENT INC.

By: /s/ Robert F. Wrobel
Title: Secretary